Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

The Impact of Comorbidity on Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Results of the RU-SKI Trial

Tatyana Ionova, PhD Professor, Tatiana Nikitina, PhD, Natalia Porfirieva, Anna Petrova, MD, Ekaterina Yu. Chelysheva, MD PhD, Oleg A. Shukhov, MD PhD, Anastasiya Bykova, MD, Galina Gusarova, MD PhD, Irina Nemchenko, MD PhD, Nikolay Tsyba, MD PhD, Anna G. Turkina, Prof., MD

Blood (2019) 134 (Supplement_1): 2925.

https://doi.org/10.1182/blood-2019-122041

Published: 2019

Journal Articles

Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Interim Results of Russian Prospective Multicenter Trial RU-SKI

Anna Petrova, MD, Ekaterina Chelysheva, MD PhD, Oleg Shukhov, MD PhD, Anastasiya Bykova, MD, Galina Gusarova, MD PhD, Irina Nemchenko, MD PhD, Nikolay Tsyba, MD PhD, Anna G Turkina, Prof., MD, Tatiana Nikitina, PhD, Natalia Porfirieva, Anna Zinkovskaya, Tatiana Ionova, DSc

Blood (2018) 132 (Supplement 1): 3023.

https://doi.org/10.1182/blood-2018-99-113360

Published: 2018

Journal Articles

Prognostic Model of Successful Tyrosine Kinase Inhibitors Discontinuation Based on the Russian RU-SKI Multicenter Prospective Study

Oleg Shukhov, MD PhD, Ekaterina Chelysheva, MD PhD, Anna Petrova, MD, Anastasiya Bykova, MD, Irina Nemchenko, MD PhD, Galina Gusarova, MD PhD, Eduard Gemdzhian, Anna G Turkina, Prof., MD

Blood (2018) 132 (Supplement 1): 1740.

https://doi.org/10.1182/blood-2018-99-116321

Published: 2018

Journal Articles

Long-Term Results and Characteristics of Pleural Effusion in Late Chronic Phase Chronic Myeloid Leukemia Patients at Dasatinib Therapy after Imatinib Failure

Galina Gusarova, MD PhD, Anastasia Bykova, MD, Alexandra Vorontsova, MD PhD, Sergey Kuznetsov, MD, Oleg Shukhov, MD, Ekaterina Chelysheva, MD PhD, Olga Lazareva, MD PhD, Svetlana Goryacheva, MD PhD, Tatyana Ivanova, MD PhD, Anna G. Turkina, MD PhD

Blood (2015) 126 (23): 5141.

https://doi.org/10.1182/blood.V126.23.5141.5141

Published: 2015

Journal Articles

Polymorphism of UGT1A1 and Frequency of Hyperbilirubinemia in Patients with Chronic Myeloid Leukemia Treated By Nilotinib

Anastasia Bykova, MD, Adhamjon Abdullaev, MD PhD, Galina Gusarova, MD PhD, Ekaterina Chelysheva, MD PhD, Svetlana Treglazova, MD, Svetlana Smirnova, MD, Anna G. Turkina, MD PhD

Blood (2014) 124 (21): 5538.

https://doi.org/10.1182/blood.V124.21.5538.5538

Published: 2014

Journal Articles

Treatment Cessation in Chronic Myeloid Leukemia As a Part of Treatment Process: Toxicity Determined and Active Stop of Tyrosine Kinase Inhibitors

Anna G. Turkina, MD PhD, Ekaterina Yu. Chelysheva, MD PhD, Vasiliy Shuvaev, Galina Gusarova, MD PhD, Anastasia Bykova, MD, Olga V. Lazareva, PhD, Oleg Shukhov, MD, Adham Abdullaev, MD PhD, Irina Martynkevich, Kudrat Abdulkadyrov, MD

Blood (2014) 124 (21): 5518.

https://doi.org/10.1182/blood.V124.21.5518.5518

Published: 2014

Journal Articles

Long-Term Results and Adverse Events Of Second Line Nilotinib Therapy After Imatinib Failure In Patients With Chronic Myeloid Leukemia In Chronic Phase In Clinical Practice

Anastasia Bykova, MD, Galina Gusarova, MD, PhD, Ekaterina Yu. Chelysheva, MD, PhD, Anna G. Turkina, MD, PhD,

Blood (2013) 122 (21): 5181.

https://doi.org/10.1182/blood.V122.21.5181.5181

Published: 2013

NARROW

The Impact of Comorbidity on Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Results of the RU-SKI Trial

Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Interim Results of Russian Prospective Multicenter Trial RU-SKI

Prognostic Model of Successful Tyrosine Kinase Inhibitors Discontinuation Based on the Russian RU-SKI Multicenter Prospective Study

Long-Term Results and Characteristics of Pleural Effusion in Late Chronic Phase Chronic Myeloid Leukemia Patients at Dasatinib Therapy after Imatinib Failure

Polymorphism of UGT1A1 and Frequency of Hyperbilirubinemia in Patients with Chronic Myeloid Leukemia Treated By Nilotinib

Treatment Cessation in Chronic Myeloid Leukemia As a Part of Treatment Process: Toxicity Determined and Active Stop of Tyrosine Kinase Inhibitors

Long-Term Results and Adverse Events Of Second Line Nilotinib Therapy After Imatinib Failure In Patients With Chronic Myeloid Leukemia In Chronic Phase In Clinical Practice

Email alerts

ASH Publications

American Society of Hematology

The Impact of Comorbidity on Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Results of the RU-SKI Trial

Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Interim Results of Russian Prospective Multicenter Trial RU-SKI

Prognostic Model of Successful Tyrosine Kinase Inhibitors Discontinuation Based on the Russian RU-SKI Multicenter Prospective Study

Long-Term Results and Characteristics of Pleural Effusion in Late Chronic Phase Chronic Myeloid Leukemia Patients at Dasatinib Therapy after Imatinib Failure

Polymorphism of UGT1A1 and Frequency of Hyperbilirubinemia in Patients with Chronic Myeloid Leukemia Treated By Nilotinib

Treatment Cessation in Chronic Myeloid Leukemia As a Part of Treatment Process: Toxicity Determined and Active Stop of Tyrosine Kinase Inhibitors

Long-Term Results and Adverse Events Of Second Line Nilotinib Therapy After Imatinib Failure In Patients With Chronic Myeloid Leukemia In Chronic Phase In Clinical Practice

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only